Status:
ACTIVE_NOT_RECRUITING
Incidence of Graves' Disease After COVID-19 Vaccination
Lead Sponsor:
Laura ICONARU
Conditions:
Graves Disease
Eligibility:
All Genders
18+ years
Brief Summary
It is well known that an infection can be a triggering factor for the development of autoimmune thyroid disease. The COVID-19 pandemic was an example of this, with several reports of both subacute thy...
Eligibility Criteria
Inclusion
- All patients who developed 'de novo' Graves' disease between March 2020 (the beginning of the COVID-19 epidemic in Belgium) and October 2022.
Exclusion
- Pregnancy
- Pre-existing Graves' disease (before March 2020)
- Diagnosis of other thyroid disease, such as subacute or painless destructive thyroiditis
- Use of thyroid-interfering drugs, such as lithium, amiodarone or immune checkpoint inhibitor therapy
Key Trial Info
Start Date :
November 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT07213141
Start Date
November 8 2022
End Date
December 31 2025
Last Update
October 8 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU St Pierre
Brussels, Belgium, 1000
2
CHU Brugmann
Brussels, Belgium, 1020
3
UZ Brussel
Jette, Belgium, 1090